Clinical trial
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who…
NCT00110305 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00110305 |
|---|---|
| Title | A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines |
| Official title | A Phase IIb Randomized, Partially Blinded, Dose-Finding Trial of TMC278 in Antiretroviral-Naive HIV-1 Infected Subjects |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus Type 1 |
| Intervention type | Drug |
| Interventions | TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs) |
| Enrollment | 368 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | May 6, 2005 |
| Last update posted | Jun 25, 2014 |
| Countries | Argentina, Austria, Brazil, China, France, Germany, Mexico, Puerto Rico, Russia, South Africa, Thailand, Uganda and 2 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: